Literature DB >> 12435805

A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

M L Trincavelli1, D Tuscano, M Marroni, A Falleni, V Gremigni, S Ceruti, M P Abbracchio, K A Jacobson, F Cattabeni, C Martini.   

Abstract

A(3) adenosine receptor activation has been previously demonstrated to result in both neuroprotective and neurodegenerative effects, depending upon specific pathophysiological conditions. This dual effect may depend on receptor regulation mechanisms that are able to change receptor availability and/or function. In the present study, we investigated desensitization, internalization, and down-regulation of native A(3) adenosine receptors in human astrocytoma cells after exposure to the agonist 2-chloro-N6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (Cl-IBMECA). Cl-IBMECA induced a concentration-dependent inhibition of adenylyl cyclase activity with an EC(50) value of 2.9 +/- 0.1 nM. The effect was suggested to be mediated by A(3) adenosine receptor subtype by the use of selective adenosine receptor antagonists. Cell treatment with pertussis toxin abolished Cl-IBMECA-mediated inhibition of adenylyl cyclase activity, evidencing an A(3) receptor coupling to inhibitory G protein. Short-term exposure to the agonist Cl-IBMECA (100 nM) caused rapid receptor desensitization, within 15 min. Agonist-induced desensitization was accompanied by receptor internalization: A(3) adenosine receptor internalized with rapid kinetics, within 30 min, after cell exposure to 100 nM Cl-IBMECA. The localization of A(3) adenosine receptors on the plasma membrane and in intracellular compartments was directly revealed by immunogold electron microscopy. After desensitization, the removal of agonist led to the restoration of A(3) adenosine receptor functioning through receptor recycling to the cell surface within 120 min. Prolonged agonist exposure (1-24 h) resulted in a marked down-regulation of A(3) adenosine receptors that reached 21.9 +/- 2.88% of control value after 24 h. After down-regulation, the recovery of receptor functioning was slow (24 h) and associated with the restoration of receptor levels close to control values. In conclusion, our results demonstrated that A(3) receptors, in astrocytoma cells, are regulated after short- and long-term agonist exposure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435805      PMCID: PMC4806643          DOI: 10.1124/mol.62.6.1373

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases.

Authors:  G Ferguson; K R Watterson; T M Palmer
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

Review 2.  G-protein coupled receptor kinases as modulators of G-protein signalling.

Authors:  M Bünemann; M M Hosey
Journal:  J Physiol       Date:  1999-05-15       Impact factor: 5.182

3.  Endocytosis and recycling of muscarinic receptors.

Authors:  J M Edwardson; P G Szekeres
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

4.  Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor.

Authors:  T M Palmer; J L Benovic; G L Stiles
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

5.  p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.

Authors:  Seong Gon Kim; Gnana Ravi; Carsten Hoffmann; Yun Jin Jung; Min Kim; Aishe Chen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2002-03-01       Impact factor: 5.858

6.  Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization.

Authors:  M L Trincavelli; D Tuscano; P Cecchetti; A Falleni; L Benzi; K N Klotz; V Gremigni; F Cattabeni; A Lucacchini; C Martini
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

7.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

Authors:  M E Olah; C Gallo-Rodriguez; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

8.  Molecular cloning and characterization of the human A3 adenosine receptor.

Authors:  C A Salvatore; M A Jacobson; H E Taylor; J Linden; R G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor.

Authors:  T M Palmer; T W Gettys; G L Stiles
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

Review 10.  Adenosine A3 receptors: novel ligands and paradoxical effects.

Authors:  K A Jacobson
Journal:  Trends Pharmacol Sci       Date:  1998-05       Impact factor: 14.819

View more
  23 in total

1.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

2.  Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes.

Authors:  Tina C Wan; Akihito Tampo; Wai-Meng Kwok; John A Auchampach
Journal:  Biochem Pharmacol       Date:  2019-01-30       Impact factor: 5.858

Review 3.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

Review 4.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

6.  Adenosine mediated desensitization of cAMP signaling enhances T-cell responses.

Authors:  Ailian Yang; Ashley D Mucsi; Melanie D Desrosiers; Jiang-Fan Chen; Jürgen B Schnermann; Michael R Blackburn; Yan Shi
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

7.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor.

Authors:  Eszter Kozma; Elizabeth T Gizewski; Dilip K Tosh; Lucia Squarcialupi; John A Auchampach; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2013-01-31       Impact factor: 5.858

9.  Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-03-08       Impact factor: 7.658

Review 10.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.